These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 31698687)

  • 1. The Regulation of Bone Metabolism and Disorders by Wnt Signaling.
    Maeda K; Kobayashi Y; Koide M; Uehara S; Okamoto M; Ishihara A; Kayama T; Saito M; Marumo K
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
    Marini F; Giusti F; Palmini G; Brandi ML
    Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacology of bone anabolic agents].
    Matsumoto T
    Nihon Rinsho; 2015 Oct; 73(10):1639-44. PubMed ID: 26529924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.
    Rossini M; Gatti D; Adami S
    Calcif Tissue Int; 2013 Aug; 93(2):121-32. PubMed ID: 23748710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The WNT system: background and its role in bone.
    Lerner UH; Ohlsson C
    J Intern Med; 2015 Jun; 277(6):630-49. PubMed ID: 25845559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases.
    Boudin E; Fijalkowski I; Piters E; Van Hul W
    Semin Arthritis Rheum; 2013 Oct; 43(2):220-40. PubMed ID: 23433961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone remodeling in the context of cellular and systemic regulation: the role of osteocytes and the nervous system.
    Niedźwiedzki T; Filipowska J
    J Mol Endocrinol; 2015 Oct; 55(2):R23-36. PubMed ID: 26307562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bone and Nutrition. Sclerostin and bone metabolism].
    Tatsumi S; Nagamoto K; Ogata M; Miyamoto K
    Clin Calcium; 2015 Jul; 25(7):1043-7. PubMed ID: 26119318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts.
    Koide M; Kobayashi Y; Yamashita T; Uehara S; Nakamura M; Hiraoka BY; Ozaki Y; Iimura T; Yasuda H; Takahashi N; Udagawa N
    J Bone Miner Res; 2017 Oct; 32(10):2074-2086. PubMed ID: 28543818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory mechanisms of sclerostin expression during bone remodeling.
    Koide M; Kobayashi Y
    J Bone Miner Metab; 2019 Jan; 37(1):9-17. PubMed ID: 30357564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Function of Wnt Ligands on Osteocyte and Bone Remodeling.
    Du JH; Lin SX; Wu XL; Yang SM; Cao LY; Zheng A; Wu JN; Jiang XQ
    J Dent Res; 2019 Jul; 98(8):930-938. PubMed ID: 31282847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role and mechanism of action of sclerostin in bone.
    Delgado-Calle J; Sato AY; Bellido T
    Bone; 2017 Mar; 96():29-37. PubMed ID: 27742498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway.
    Appelman-Dijkstra NM; Papapoulos SE
    Nat Rev Endocrinol; 2018 Oct; 14(10):605-623. PubMed ID: 30181608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The canonical Wnt/β-catenin pathway: From the history of its discovery to clinical application].
    Grebennikova TA; Belaya ZE; Rozhinskaya LY; Melnichenko GA
    Ter Arkh; 2016; 88(10):74-81. PubMed ID: 28635854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts.
    Baum R; Gravallese EM
    Clin Rev Allergy Immunol; 2016 Aug; 51(1):1-15. PubMed ID: 26411424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin: recent advances and clinical implications.
    Honasoge M; Rao AD; Rao SD
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia Signaling in the Skeleton: Implications for Bone Health.
    Yellowley CE; Genetos DC
    Curr Osteoporos Rep; 2019 Feb; 17(1):26-35. PubMed ID: 30725321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin: from bench to bedside.
    Tanaka S; Matsumoto T
    J Bone Miner Metab; 2021 May; 39(3):332-340. PubMed ID: 33206222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The osteocyte plays multiple roles in bone remodeling and mineral homeostasis.
    Chen H; Senda T; Kubo KY
    Med Mol Morphol; 2015 Jun; 48(2):61-8. PubMed ID: 25791218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders.
    Pietrzyk B; Smertka M; Chudek J
    Adv Clin Exp Med; 2017 Nov; 26(8):1283-1291. PubMed ID: 29264888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.